Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates

Gary Wong, Jason S. Richardson, S. Pillet, Trina Racine, Ami Patel, Geoff Soule, Jane Ennis, Jeffrey Turner, Xiangguo Qiu, Gary P. Kobinger

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvanted human adenovirus serotype 5 (Ad5)-vectored vaccine (Ad5-Zaire EBOV glycoprotein) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24 hours following EBOV challenge, respectively. The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV.

Original languageEnglish (US)
Pages (from-to)S379-S383
JournalJournal of Infectious Diseases
StatePublished - Oct 1 2015
Externally publishedYes


  • Ebola
  • adenovirus
  • nonhuman primates
  • post-exposure
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates'. Together they form a unique fingerprint.

Cite this